Ductal carcinoma in situ screening
This article was originally published in The Gray Sheet
Researchers should improve breast magnetic resonance imaging techniques to enable discrimination between non-invasive ductal carcinoma in situ (DCIS) that requires intervention, and that which can be managed more conservatively, according to a Sept. 24 National Institutes of Health "State-of-the-Science" conference statement on DCIS diagnosis and management. DCIS, a spectrum of abnormal cells confined to the breast duct, is a risk factor for invasive breast cancer. Breast MRI is more sensitive than mammography and has been used to screen for DCIS, but technological advances may be required to prevent over-detection of insignificant lesions and to better risk-stratify patients who need more aggressive treatment, the conference panel concluded at the Sept. 22-24 meeting in Bethesda, Md
You may also be interested in...
Butterfly Network chose SPAC route with Longview Acquisition Corp. to scale its business and expand into the home market in 2021.
Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.
With Warp Speed Decisions Already Made, Transitioning To Biden Admin Should Be No Trouble, Slaoui Says
As vaccines near availability, Moncef Slaoui says his full-time role at OWS may be ending. He has not met with the Biden Transition team, but notes that other Warp Speed officials have.